Association of Behçet’s disease with the risk of metabolic syndrome and its components: a systematic review and meta-analysis

The present meta-analysis aimed to elucidate the association of Behçet’s disease (BD) with the risk of metabolic syndrome (MetS) and its components. Observational cohort studies were searched from the Embase, Web of Science, Medline, and Cochrane Library databases. The primary outcome was the associ...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine Vol. 23; no. 6; pp. 2855 - 2866
Main Authors: Chen, Tingqiao, Shao, Xinyi, Li, Hao, Chen, Yangmei, Liu, Lin, Zhong, Judan, Chen, Jin
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01.10.2023
Springer Nature B.V
Subjects:
ISSN:1591-9528, 1591-8890, 1591-9528
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present meta-analysis aimed to elucidate the association of Behçet’s disease (BD) with the risk of metabolic syndrome (MetS) and its components. Observational cohort studies were searched from the Embase, Web of Science, Medline, and Cochrane Library databases. The primary outcome was the association of BD with the risk of MetS and its relevant components. Effect estimates with odds ratios (ORs) were pooled using either the random-effects or fixed-effects models, according to heterogeneity. Leave-one-out sensitivity analyses were used to determine the stability of the results. Twenty-three studies, comprising 42,834 patients with BD, were included. Overall, a significant association between BD and the risk of MetS was found (pooled OR 2.26; 95% confidence interval [CI] 1.61–3.17; P  < 0.0001). Among the components of MetS, significant associations were found between BD and diabetes mellitus (OR 1.21; 95% CI 1.10–1.33; P  < 0.0001), BD and hypertension (OR 1.39; 95% CI 1.13–1.70; P  = 0.002), and BD and dyslipidemia (OR 1.21; 95% CI 1.01–1.45; P  = 0.04). Our study indicated an association between BD and the risk of MetS and some of its components (diabetes mellitus, hypertension, and dyslipidemia). Physician should consider these associations so that specific treatments are available for patients with comorbidities. Moreover, patients with BD should regularly monitor their blood pressure, fasting plasma glucose, and blood lipid levels.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:1591-9528
1591-8890
1591-9528
DOI:10.1007/s10238-023-01044-x